Suppr超能文献

肿瘤抑制因子p190RhoGAP以不同方式启动细胞凋亡并赋予乳腺癌细胞对多西他赛的敏感性。

The Tumor Suppressor, p190RhoGAP, Differentially Initiates Apoptosis and Confers Docetaxel Sensitivity to Breast Cancer Cells.

作者信息

Ludwig Kirsten, Parsons Sarah J

机构信息

Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, VA, USA.

出版信息

Genes Cancer. 2011 Jan;2(1):20-30. doi: 10.1177/1947601911402680.

Abstract

p190RhoGAP (p190) is a negative regulator of RhoGTPases and a putative tumor suppressor, whose mechanism of tumor suppression is poorly defined. Ectopic expression of p190 induces various morphological phenotypes, including multinucleation, dendrite-like formation, and chromatin condensation, suggesting an involvement in apoptosis. We examined the possibility that p190 can function as a tumor suppressor by regulating induction of apoptosis. We show that the predominant phenotype of p190 overexpression in a variety of cell lines is apoptosis, which is mediated through p190's regulation of Rho and caspases. The secondary phenotypes, multinucleation and dendrite-like formation, are determined by transformation status, not cell lineage, and appear to be intermediate phenotypes in the p190-induced apoptotic pathway. Finally, we show that p190 levels can regulate the apoptotic response of breast cancer cell lines to docetaxel through its regulation of Rho. Together, these findings suggest that one mechanism by which p190 can mediate its tumor-suppressive function is through regulation of Rho-activated cell death pathways and that this function can be exploited to optimize the action of cytoskeletal-based chemotherapeutics, such as the taxanes.

摘要

p190RhoGAP(p190)是RhoGTP酶的负调节因子和一种假定的肿瘤抑制因子,其肿瘤抑制机制尚不清楚。p190的异位表达会诱导多种形态学表型,包括多核化、树突样形成和染色质浓缩,提示其参与细胞凋亡。我们研究了p190是否可通过调节细胞凋亡的诱导而发挥肿瘤抑制因子的作用。我们发现,在多种细胞系中p190过表达的主要表型是细胞凋亡,这是通过p190对Rho和半胱天冬酶的调节介导的。次要表型,即多核化和树突样形成,由转化状态而非细胞谱系决定,并且似乎是p190诱导的凋亡途径中的中间表型。最后,我们表明p190水平可通过其对Rho的调节来调控乳腺癌细胞系对多西他赛的凋亡反应。总之,这些发现表明p190介导其肿瘤抑制功能的一种机制是通过调节Rho激活的细胞死亡途径,并且这种功能可用于优化基于细胞骨架的化疗药物(如紫杉烷类)的作用。

相似文献

2
Opposing roles of p190RhoGAP and Ect2 RhoGEF in regulating cytokinesis.
Cell Cycle. 2008 Jul 1;7(13):2003-12. doi: 10.4161/cc.7.13.6128.
4
p190RhoGAP is cell cycle regulated and affects cytokinesis.
J Cell Biol. 2003 Nov 10;163(3):571-82. doi: 10.1083/jcb.200308007.
5
Mitotic down-regulation of p190RhoGAP is required for the successful completion of cytokinesis.
J Biol Chem. 2010 Aug 27;285(35):26923-26932. doi: 10.1074/jbc.M110.103804. Epub 2010 Jun 9.
6
p190RhoGAP negatively regulates Rho activity at the cleavage furrow of mitotic cells.
Exp Cell Res. 2009 May 1;315(8):1347-59. doi: 10.1016/j.yexcr.2009.02.014. Epub 2009 Feb 27.
7
A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.
J Biol Chem. 2003 Nov 7;278(45):44617-25. doi: 10.1074/jbc.M308929200. Epub 2003 Aug 25.
8
Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane.
Mol Biol Cell. 2006 Nov;17(11):4827-36. doi: 10.1091/mbc.e06-02-0132. Epub 2006 Sep 13.

引用本文的文献

2
p190RhoGAPs, the and -Encoded Proteins, in Health and Disease.
Cells. 2019 Apr 12;8(4):351. doi: 10.3390/cells8040351.
4
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.
Oncotarget. 2018 May 22;9(39):25545-25556. doi: 10.18632/oncotarget.25370.
5
Regulation of Rho GTPase activity at the leading edge of migrating cells by p190RhoGAP.
Small GTPases. 2019 Mar;10(2):99-110. doi: 10.1080/21541248.2017.1280584. Epub 2017 Mar 13.
8
Glucocorticoid receptor DNA binding factor 1 expression and osteosarcoma prognosis.
Tumour Biol. 2014 Dec;35(12):12449-58. doi: 10.1007/s13277-014-2563-z. Epub 2014 Sep 4.
9
Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.
Biomed Res Int. 2014;2014:396947. doi: 10.1155/2014/396947. Epub 2014 Jul 20.
10
RhoA is down-regulated at cell-cell contacts via p190RhoGAP-B in response to tensional homeostasis.
Mol Biol Cell. 2013 Jun;24(11):1688-99, S1-3. doi: 10.1091/mbc.E12-05-0386. Epub 2013 Apr 3.

本文引用的文献

1
Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Cancer Biol Ther. 2010 Jun 1;9(11):875-84. doi: 10.4161/cbt.9.11.11634. Epub 2010 Jun 26.
2
Microtubules regulate migratory polarity through Rho/ROCK signaling in T cells.
PLoS One. 2010 Jan 19;5(1):e8774. doi: 10.1371/journal.pone.0008774.
3
Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells.
Int J Gynecol Cancer. 2009 Dec;19(9):1473-80. doi: 10.1111/IGC.0b013e3181c03909.
4
6
p190RhoGAP negatively regulates Rho activity at the cleavage furrow of mitotic cells.
Exp Cell Res. 2009 May 1;315(8):1347-59. doi: 10.1016/j.yexcr.2009.02.014. Epub 2009 Feb 27.
7
A mechanosensitive transcriptional mechanism that controls angiogenesis.
Nature. 2009 Feb 26;457(7233):1103-8. doi: 10.1038/nature07765.
8
Docetaxel-related side effects and their management.
Eur J Oncol Nurs. 2009 Feb;13(1):49-59. doi: 10.1016/j.ejon.2008.10.003. Epub 2009 Feb 7.
9
The cytoskeleton and cancer.
Cancer Metastasis Rev. 2009 Jun;28(1-2):5-14. doi: 10.1007/s10555-008-9166-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验